Opinion|Videos|August 12, 2024
Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection
A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.
Advertisement
Video content above is prompted by the following questions:
- Outside of biomarkers, what clinical factors also lead to immune checkpoint inhibitor therapy underperformance?
- How can patient selection be optimized among those less likely to respond to immune checkpoint inhibitor therapy?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
3
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
4
Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial
5
